РОЗАЦЕА- ЛЕЧЕНИЯ В СИСТЕМНЫХ РЕТИНОИДОВ
Keywords:
Розацеа, лечение, изотретиноин, «Изона».Abstract
Розацеа – хронический воспалительный дерматоз, характеризующийся поражением кожи лица в виде эритемы и папулопустулезных элементов, фим и поражения глаз. Розацеа представляет собой ангионевроз, локализующийся
преимущественно в зоне иннервации тройничного нерва и обусловленный различными причинами, которые можно объединить в следующие группы: сосудистые нарушения; изменения в соединительной ткани дермы; микроорганизмы; дисфункция пищеварительного тракта; иммунные нарушения; изменения сально-волосяного аппарата; оксидативный стресс;
климатические факторы; психовегетативные расстройства.
References
1. Tan J; ROSCO coauthors. Updating the diagnosis, classification and assessment
of rosacea by effacement of subtypes: reply from the author. Br J Dermatol. 2017
2. Tan J., Schofer H., Araviiskaia E., Audibert F, Kerrouche N, Berg M; Prevalence
of rosacea in the general population of Germany and Russia – the RISE study.
JEADV, 2016 Mar;30(3):428-34.
3. Elewsky B, Draelos Z, Dreno B. Rosacea – global diversity and optimized outcome:
proposed international consensus from the Rosacea International Expert Group.
JEADV 2011;25:188-200.
4. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and
subtype classification. J Am Acad Dermatol. 2004 Sep;51(3):327-41.
5. Powell FC. Rosacea. N Engl J Med 2005; 352: 793–803. 2 Baldwin HE. Systemic
therapy for rosacea. Skin Therapy Lett 2007; 12: 1–5, 9.
6. Garnis-Jones S. Psychological aspects of rosacea. J Cutan Med Surg 1998; 2 (Suppl.
4): 4–9.
7. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989;
69: 419–423.
8. Самцов А.В. Акне и акнеиформные дерматозы. Монография – М.: OOO
«ЮТКОМ», 2009. – 208 с.: ил.
9. Powell F.C, Rosacea. N. Engel J. Med. 2005; 352: 793-803
10. Руководство по дерматокосметологии / Под ред. Аравийской Е.Р.и
Соколовского Е.В.. – CПб.: ООО «Издательство Фолиант:», 2008. – 632 с.
11. Lacey N, Delaney S, Kavanagh K et al. Mite related bacterial antigens stimulate
inflammatory cells in rosacea. Br J Dermatol 2007;157: 474-481.
12. Frank S et al. Regulation of VEGF expression in cultured keratrinocytes.
Implications for normal and impaired wound healing. J. Biol. Chem. 1995; 270:
12607 – 12613
13. Gomaa A, Yaar M, Eyada M et al. Lymphahgiogenesis and angiogenesis in non
phymatosis rosacea. J Cutan Pathol 2007;34:748-753.
14. Whitfeld M, Gunasingam N, Leow L et al. Staphylococcus epidermidis: a possible
role in thye pustules of rosacea. J Am Acad Dermatol 2011;64:49-59.
15. Moran A.P.Patogenic properties of Helicobakter pylori. Scan.J. Gastroenterol.
1996;. 31; 215; 22-31.
16. Wolf R. Acne rosacea and Helycobacter pylori betrothed .Int.J.Dermatol.
1996;35;4;: 302 – 303.
17. Rebora A., Drago F., Parodi A. May Helicobacter pylori be important for
dermatologist. Dermatology 1995; 191; 6 - 8.
18. Diaz C., Oсallaghan C.J., Khan A., Ilchyshyn A. Rosacea: a cutaneous marker of
Helicjbacter pylori infection? Result of a pylot studi. Acta Derm. Venerol. 2003; 4:
282 – 286
19. Bamford J. Rosacea: current thouthts on origin. Semin Cutan Med Surg
2001;20:199-206. Zuber T.Rosacea.Prim Care 2000;27:309-318.
20. Wilkin J., Dahl M., Detmar M., Drake L. et al. Standard classification of rosacea:
Report of the National Rosacea Society Expert Committee on the Classification and
Staging of Rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584-7.
21. Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Schäfer G. Defining
treatment success in rosacea as “clear” may provide multiple patient benefit: results
of pooled analysis. Journal of Dermatological Treatment, 2017;28 (5):469-474.
22. van Zuuren EJ, Graber MA, Hollis S et al. Interventions for rosacea Cochrane
Database Syst Rev 2005; Jul 20: CD003262.
23. Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of
potential
correlations
between pathophysiologic mechanisms, clinical
manifestations, and management of rosacea. Cutis. 2013 Mar;91(3 Suppl):1-8
24. Sneddon I. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649
653.
25. Thilboutot D. Efficasy and safety of subantimicrobial-dose doxycycline for the
threatment of rosacea J. Am. Acad. Dermatol. 2005; 52: 3-P 17.
26. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline
therapy for rosacea. Br J Dermatol 1980; 102: 443–445.
27. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211
1212.
28. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage
tell us? Australas J Dermatol. 2013 Aug;54(3):157-62.
29. Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG et al. Systemic isotretinoin in
the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical
study. J Dtsch Dermatol Ges. 2010 Jul;8(7):505-15.
30. Hofer T. Continuous ‘microdose’ isotretinoin in adult recalcitrant rosacea. Clin Exp
Dermatol 2004; 29: 204–205.
31. Gollnick H. Optimal Isotretinoin Dosing for Rosacea, 18th Congress of the
European Academy of Dermatology and Venereology, Berlin 2009.
32. Gollnick H.P., Bettoli V., Lambert J., Araviiskaia E., et al. Aconsensus-based
practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol
Venereol. 2016 Sep;30(9):1480-90.
33. Панкина Е.С. Нарушения микроциркуляции кожи лица при розацеа и методы
их коррекции. Автореф канд дис СПб,2008, 20 c.
34. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M,
Lynde C, Liu H, Jacovella J. Efficacy and safety of ivermectin 1% cream in
treatment of papulopustular rosacea: results of two randomized, double-blind,
vehicle-controlled pivotal studies. JDD, 2014;13(3):316-323.
35. Ventre E, Rozières A, Lenief V, Albert F, Rossio P, Laoubi L, Dombrowicz D,
Staels B, Ulmann L, Julia V, Vial E, Jomard A, Hacini-Rachinel F, Nicolas JF,
Vocanson M. Topical ivermectin improves allergic skin inflammation. Allergy.
2017 Aug;72(8):1212-1221.
36. Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH,
Jacovella J; Ivermectin Phase III study group. Superiority of ivermectin 1%
cream over metronidazole 0·75% cream in treating inflammatory lesions of
